EU/3/20/2388: Orphan designation for the treatment of congenital muscular dystrophy

Human laminin-111, recombinant


On 6 January 2021, orphan designation EU/3/20/2388 was granted by the European Commission to Maxia Strategies-Europe Limited, Ireland, for human laminin-111, recombinant (also known as rhLAM-111) for the treatment of congenital muscular dystrophy.

Key facts

Active substance
Human laminin-111, recombinant
Intended use
Treatment of congenital muscular dystrophy
Orphan designation status
EU designation number
Date of designation

Maxia Strategies-Europe Limited
13 Baggot Street Upper
Dublin 4
Co. Dublin
D04 W7K5
Tel: +353 (1) 254 9909

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating